Journal of Clinical Oncology, Vol 1, 135-137, Copyright © 1983 by American Society of Clinical Oncology
Methyl-CCNU, 5-fluorouracil, vincristine, and streptozocin (MOF-STREP) in metastatic colo-rectal carcinoma
MD Weltz, DJ Perry, J Blom and WM Butler
Forty patients with metastatic colorectal carcinoma who had received no
prior chemotherapy were entered onto a trial of methyl-CCNU, 5-
fluorouracil, vincristine, and streptozocin (MOF-STREP). Ten of 40 (25%)
responded. Two patients (5%) achieved a complete response and eight
patients (20%) a partial response. In addition, 10 patients previously
treated with chemotherapy received the MOF-STREP regimen; 1 of 10 (10%)
responded. The duration of the complete responses were 5 and 16 mo,
respectively. The median duration of the partial responses was 4 mo with a
range of 1-16 mo. The median survival of the 11 responders was 14 mo.
Median survival of the 39 nonresponders was 5 months. Responders lived
significantly longer than nonresponders (p = 0.03, log-rank). Toxicity was
severe with nausea and vomiting common after streptozocin and
myelosuppression requiring dose reductions in 70% of patients. We compare
our findings using this regimen to those of two previously reported trials.
